Ventricular Tachycardia: What It Is, Why It Happens, and How We Treat It

When patients hear "ventricular tachycardia" for the first time, the word lands hard. It sounds technical, frightening, and final. I want to take some of that weight off you. Ventricular tachycardia is a fast heart rhythm that starts in the bottom chambers of your heart, the ventricles. Some forms are dangerous and demand urgent care. Other forms are quiet, brief, and never need more than monitoring. The right care depends entirely on which kind you have and what your heart looks like underneath.

I'm Dr. Damian Rasch, a cardiologist in Encinitas. I've sat across from patients freshly diagnosed with VT after a syncope episode, after an ICD shock, after an Apple Watch alert, and after a routine stress test that caught a few extra beats. Each story called for a different conversation. This article is meant to give you the version of that conversation you'd get if we had an unhurried hour together.

What Ventricular Tachycardia Actually Is

Your heart has four chambers. The two on top are the atria, and the two on the bottom are the ventricles. The ventricles do the heavy lifting of pumping blood to your lungs and to the rest of your body. Normally the electrical signal that tells those ventricles when to squeeze starts in a small node up top, travels through a special wiring system, and arrives in both ventricles at almost the same instant. That coordinated squeeze is what creates a strong, efficient heartbeat.

In ventricular tachycardia (VT), the electrical signal stops coming from the normal place. Instead it fires from somewhere down in the ventricles themselves, looping or sparking on its own at a fast rate. The official definition is three or more beats in a row coming from the ventricles at a rate above 100 per minute. In real life most VT runs at 150 to 250 per minute.

When the ventricles beat that fast, they don't have time to fill properly. The squeeze is also poorly coordinated, since the signal isn't traveling through the normal wiring. The result is reduced output. That's why VT can cause lightheadedness, palpitations, chest pressure, fainting, or in the worst cases, sudden cardiac arrest.

Sustained VT, Nonsustained VT, and the Vocabulary You'll Hear

When I tell a patient they had VT, the next thing I usually say is what kind. The labels matter because they shape what we do next.

Nonsustained VT (NSVT) means three or more beats in a row from the ventricles, lasting less than 30 seconds, that stop on their own. NSVT shows up all the time on heart monitors. In a healthy heart with no scar, a few short runs of NSVT are usually nothing to lose sleep over. In a heart with weak pumping function or significant scar, even short NSVT can be a warning sign that deserves a closer look.

Sustained VT lasts longer than 30 seconds, or it lasts shorter but causes you to pass out or crash hemodynamically before then. Sustained VT is the form that usually brings someone to the emergency room. It needs to be stopped, and once stopped it needs an explanation.

Monomorphic VT means every beat looks the same on the EKG. The signal is coming from one consistent spot or one consistent loop. This is the most common pattern when there's a scar in the heart from a previous heart attack or from a cardiomyopathy.

Polymorphic VT means the beats keep changing shape. This pattern often points to acute ischemia, a problem with the QT interval, or an inherited electrical disorder.

Torsades de pointes is a special kind of polymorphic VT that happens when the QT interval on your EKG is too long. The QRS complexes appear to twist around the baseline, which is where the French name "twisting of the points" comes from. Long QT can be inherited or caused by medications. Many common drugs prolong QT, including some antibiotics, antifungals, antinausea agents, methadone, and certain antidepressants.

Ventricular fibrillation (VF) is what happens when the ventricles abandon any rhythm at all and just quiver. There's no pumping at that point. VF causes cardiac arrest within seconds and requires defibrillation immediately. VT can degenerate into VF.

Accelerated idioventricular rhythm (AIVR) is a slower cousin, running 40 to 100 per minute. It often shows up briefly when blood flow returns after a heart attack or after a coronary intervention. AIVR is usually self-limited and doesn't need treatment.

Electrical storm is the term we use when someone has three or more sustained VT episodes in a 24-hour period. Storm is a genuine emergency, and it gets its own playbook.

Why Ventricular Tachycardia Happens

Most VT falls into one of two big buckets, and the bucket determines almost everything about prognosis and treatment.

Scar-related VT

The first bucket is scar-related VT. When the heart muscle has been damaged, by a previous heart attack, by a viral infection that left dilated cardiomyopathy, by hypertrophic cardiomyopathy, by sarcoidosis, by arrhythmogenic right ventricular cardiomyopathy (ARVC), or by chronic high blood pressure that finally weakened the muscle, the damage leaves behind areas of dead and scarred tissue mixed with surviving muscle fibers.

Electrical signals can get trapped in those mixed areas. They travel through a slow surviving fiber, come out, find the rest of the heart ready to fire again, and loop back in. That loop becomes a self-sustaining circuit, and the result is sustained monomorphic VT. Scar-related VT is by far the most common kind we see in adults, and it's the form most associated with serious risk.

Idiopathic VT in a structurally normal heart

The second bucket is idiopathic VT, which means VT in a heart that looks completely normal on imaging and on stress testing. The most common forms are right ventricular outflow tract VT, which arises from a small focus just below the pulmonary valve, and fascicular VT, which originates in the left bundle branch. Both have classic patterns on the EKG that an experienced reader can spot.

Idiopathic VT usually carries an excellent prognosis. The heart is structurally fine, the rhythm doesn't degenerate into VF the way scar-related VT can, and catheter ablation cures it most of the time.

Inherited and channelopathy causes

Some patients have a normal-looking heart but an abnormal electrical system at the cellular level. These are the channelopathies: long QT syndrome, short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). Each is caused by inherited problems in the channels that move sodium, potassium, or calcium across heart cells. The clue is usually a family history of fainting, sudden death, or unexplained accidents in a young person, sometimes paired with a particular pattern on the EKG.

Reversible triggers

VT can also be triggered by problems that don't reflect a permanent issue with the heart. Low potassium, low magnesium, severe acidosis, oxygen deprivation, drug toxicity (digoxin, certain antiarrhythmics, illicit stimulants), QT-prolonging medications, and acute coronary ischemia all qualify. When the trigger is fixed, the rhythm usually goes away and doesn't return. That's an entirely different category of patient than someone whose VT comes from a fixed scar.

Symptoms and How VT Feels

Patients describe VT in a wide range of ways. Some feel an obvious pounding in the chest, often in the throat as well, that hits suddenly and stops just as suddenly. Others feel a heavy chest, shortness of breath, or a wave of lightheadedness. Many faint. A handful collapse with no warning at all and end up in cardiac arrest. And some patients have no symptoms whatsoever, with the rhythm caught only by an event monitor or a pacemaker download.

The symptom severity correlates somewhat with how fast the VT is, how long it lasts, and how good the underlying heart function is. A patient with a normal heart can sometimes tolerate fast VT for minutes with only palpitations. A patient with a weak heart at the same rate may collapse in seconds. That difference matters because it changes how quickly we have to act.

If you've ever had unexplained fainting, especially during exercise or with no warning sign at all, that's worth a careful workup. Fainting from a vasovagal response (the kind that happens with dehydration, prolonged standing, or a needle stick) feels different and has its own pattern. Fainting from VT or from another arrhythmia tends to be sudden, without the long warm-up of nausea and tunnel vision.

How We Diagnose Ventricular Tachycardia

The gold standard is catching the rhythm on a tracing. That can happen on a hospital telemetry monitor, on a 12-lead EKG taken during the event, on a Holter monitor at home, on an event monitor or patch worn for two to four weeks, or on an implantable loop recorder placed under the skin for up to three years.

When we look at a wide-complex tachycardia on the EKG, we have to decide whether it's VT or whether it's a fast supraventricular rhythm conducting with aberrancy. The default rule is that any wide-complex tachycardia in an adult with structural heart disease is VT until proven otherwise. The features that confirm VT include AV dissociation (the upper and lower chambers beating independently), capture beats and fusion beats, very wide QRS complexes, and certain morphology patterns described in published algorithms (Brugada and Vereckei). For patients, what matters is that we err strongly on the side of treating wide-complex tachycardia as VT, because the consequences of getting it wrong are serious.

The Workup After Diagnosis

Once we've documented VT, we want to understand the heart underneath. The workup almost always includes:

Echocardiogram to measure pumping strength, wall motion, and look for hypertrophy, dilation, or valvular issues. The ejection fraction (EF) is a number you'll hear repeatedly, and it drives much of what comes next.

Cardiac MRI in many cases, since MRI can map scar with much higher resolution than echo. Late gadolinium enhancement on MRI shows where fibrosis lives. The location and amount of scar give us prognostic information and can change whether we recommend a defibrillator.

Ischemic evaluation, which might be a stress test, a coronary CT, or a coronary angiogram, depending on your risk factors and symptoms. We don't want to put a defibrillator in someone whose VT was triggered by a blocked artery that we could open instead.

Electrophysiology study (EP study) in selected patients. This is a catheter procedure where we map the electrical activity of the heart from inside, sometimes deliberately inducing the VT to characterize it and then ablating the circuit if it can be reached.

Genetic testing when an inherited syndrome is suspected, especially in younger patients with structurally normal hearts or in families with a history of sudden death. Testing has gotten faster and cheaper, and it can change management for both the patient and their relatives.

Treating VT in the Moment

Acute treatment depends on whether the patient is stable.

If the patient is unstable (low blood pressure, chest pain, shortness of breath at rest, altered mental status, or evidence of organ underperfusion), the answer is electrical cardioversion. Synchronized shock through the chest restores normal rhythm in most cases. If the rhythm has degenerated into VF or pulseless VT, we deliver an unsynchronized defibrillation and follow standard CPR algorithms.

If the patient is stable, we have time for medications. The 2017 AHA/ACC/HRS guideline for ventricular arrhythmias supports IV procainamide, IV amiodarone, or IV lidocaine. The PROCAMIO trial in 2017 randomized 74 patients with stable monomorphic VT to procainamide versus amiodarone and found that procainamide had a higher termination rate (67 percent versus 38 percent) and fewer adverse events. That's why many electrophysiologists now reach for procainamide first when it's available, though amiodarone remains a reasonable choice and is more familiar in many ERs.

For torsades de pointes, the treatment is different. We give IV magnesium, correct potassium and any underlying electrolyte problem, stop any QT-prolonging medication, and sometimes pace the heart to a faster rate (overdrive pacing) so the QT interval shortens.

For VT triggered by acute ischemia, the priority is opening the blocked artery as fast as possible. Once flow is restored, the rhythm often settles.

Long-Term Medical Therapy

After an episode of VT, ongoing medical therapy depends on the cause.

Beta blockers are the foundation for most patients with structural heart disease. They reduce sympathetic drive to the heart, raise the threshold for arrhythmia, and improve survival in patients with reduced EF.

Amiodarone is the most effective antiarrhythmic we have, but it carries real toxicity over time. Long-term amiodarone can affect the lungs, thyroid, liver, eyes, and skin. We use it carefully, monitor labs regularly, and reserve it for patients whose VT can't be controlled with safer agents or whose alternative is repeated defibrillator shocks.

Sotalol combines beta blockade with potassium channel blockade. It works well for many patients but requires QT monitoring at initiation, usually as a brief inpatient stay.

Mexiletine is an oral relative of lidocaine. It's used for adjunct therapy, often in long QT type 3 and in some scar-related VT.

For all of these, we balance the rhythm benefit against side effects and the patient's quality of life. The goal is rhythm control that doesn't make daily life worse.

Implantable Cardioverter-Defibrillators (ICDs)

An implantable cardioverter-defibrillator (ICD) is a small device placed under the skin near the collarbone, with a wire (or wires) running through a vein into the heart. It watches every heartbeat and, if it detects sustained VT or VF, it delivers anti-tachycardia pacing or a shock to restore normal rhythm. ICDs save lives. The trial evidence is strong and consistent.

We talk about ICDs in two categories: secondary prevention (you've already had a sustained VT or cardiac arrest) and primary prevention (you haven't had an event yet but your risk is high enough to act).

Secondary prevention is the easier conversation. If you've survived a cardiac arrest from VT or VF that wasn't from a fully reversible cause, an ICD is recommended. The same applies for sustained VT that caused syncope or hemodynamic compromise. These are Class I recommendations in both the 2017 AHA/ACC/HRS guideline and the 2022 ESC guideline.

Primary prevention is more nuanced. The landmark trials are MADIT-II, SCD-HeFT, and DANISH. MADIT-II in 2002 enrolled 1232 patients with prior myocardial infarction and an EF of 30 percent or less and randomized them to ICD or conventional care. The ICD group had a 31 percent reduction in all-cause mortality. SCD-HeFT in 2005 enrolled 2521 patients with EF of 35 percent or less, both ischemic and nonischemic, in NYHA class II or III heart failure. The ICD reduced mortality by 23 percent compared to placebo, while amiodarone showed no benefit. DANISH in 2016 enrolled 1116 patients with nonischemic cardiomyopathy and EF of 35 percent or less. Sudden death dropped, but all-cause mortality didn't change overall. The benefit was clearer in younger patients.

The practical takeaway: most patients with EF of 35 percent or less, NYHA class II or III, and at least 90 days of optimized medical therapy after revascularization, qualify for a primary prevention ICD. The conversation gets more individualized in nonischemic cardiomyopathy, in older patients with multiple competing health problems, and in patients whose values lean against device-based therapy.

A wearable defibrillator (often called by the brand name LifeVest) is sometimes used as a bridge during the first months after a heart attack or during the wait period before deciding on a permanent ICD. It's not a substitute for an ICD long term.

Catheter Ablation for VT

Catheter ablation has come a long way. We now use detailed three-dimensional electroanatomic mapping systems that build a model of the heart's chambers and color-code voltage and activation timing. The goal of an ablation is to find the circuit that sustains VT and either burn or freeze it so it can no longer carry the signal.

For idiopathic VT in a structurally normal heart, ablation is often curative. RVOT VT and fascicular VT both have ablation success rates above 85 percent, with low complication rates. For young patients without scar, ablation is an attractive first-line option that may eliminate the need for chronic medications.

For scar-related VT, ablation is usually paired with antiarrhythmic medication and an ICD rather than replacing them. The VANISH trial in 2016 randomized 259 patients with ischemic VT despite amiodarone to either ablation or escalated antiarrhythmic therapy. Ablation reduced the composite of death, VT storm, and appropriate ICD shock. The PARTITA and BERLIN-VT trials extended the question to whether ablation should be done earlier in the course of disease, with mixed but mostly encouraging results.

Ablation is not free of risk. Vascular access complications, cardiac perforation, stroke, and worsening of heart function can occur. In experienced centers, the risk of major complications is in the low single digits. The decision to proceed with ablation is individualized, and patients with severe heart failure or significant comorbidities sometimes need pre-procedural mechanical circulatory support to tolerate the case.

Managing Electrical Storm

When a patient has multiple VT episodes within a day, often firing the ICD again and again, we call it electrical storm. It is one of the most stressful and serious situations in cardiology, and it requires a stepwise plan.

First, sedation, sometimes deep enough to require intubation, since the catecholamine surge from being awake during repeated shocks itself fuels more VT. Then IV beta blockade, often with esmolol or metoprolol, to blunt sympathetic drive. IV amiodarone is layered on. Reversible triggers (electrolyte abnormalities, ischemia, drug effects) get fixed. If the rhythm continues, we move to advanced sympathetic blockade, including stellate ganglion block, in which a local anesthetic is injected near the nerve cluster in the neck that drives sympathetic outflow to the heart.

Mechanical circulatory support (such as an Impella device or VA-ECMO) may be used to stabilize hemodynamics. Urgent catheter ablation in this setting can be life-saving. Storm is a team sport, and patients in storm are usually transferred to a center with electrophysiology, advanced heart failure, and ECMO capability if they aren't already there.

Living With Ventricular Tachycardia

A diagnosis of VT changes a few things in daily life, but most patients return to a routine that looks much like the one they had before.

Driving: states have variable rules, but the general principle is that after an episode of sustained VT or an ICD shock, there's a recommended waiting period before driving a private vehicle, often three to six months without recurrence. Commercial driving rules are stricter. We work through this individually based on what your VT looked like and what device you have.

Exercise: for most patients with idiopathic VT, normal exercise is fine. For patients with scar-related VT, ARVC, HCM, or channelopathies, exercise restrictions are individualized. Some inherited rhythm disorders require avoidance of competitive sports. Cardiac rehabilitation is often appropriate after an event and is usually safe with proper monitoring.

Travel: air travel is fine with an ICD. The metal detector and body scanner are safe, though it's reasonable to ask for a hand search if you'd prefer not to walk through. Carry your device card.

Mental health: living with the possibility of an ICD shock causes anxiety in many patients. Receiving a shock, especially when awake, is genuinely traumatic for some. Cardiologists, electrophysiologists, and mental-health clinicians who specialize in chronic illness can all help. You're not weak for finding it hard.

Pregnancy: for women with structural heart disease and known VT, pregnancy planning involves cardiology, maternal-fetal medicine, and electrophysiology together. Many medications used in VT are not safe in pregnancy, and the cardiovascular changes of pregnancy can themselves trigger arrhythmia. Pre-conception counseling is the right time to make a plan.

Common Questions Patients Ask

Will I die from this?

Most patients with treated VT do not die from it. Outcomes depend heavily on the cause. Idiopathic VT in a normal heart carries excellent long-term prognosis. Scar-related VT in a heart with poor pumping function has higher risk, but ICD therapy and modern medications have changed those numbers dramatically. The single most predictive factor is the underlying heart, not the arrhythmia itself.

Can VT come back after ablation?

For idiopathic VT, recurrence after a successful ablation is uncommon. For scar-related VT, recurrence is more frequent, sometimes 30 to 50 percent over a few years, depending on the substrate. That doesn't mean ablation failed. Reducing the burden of VT, even without complete cure, lowers ICD shocks and improves quality of life.

Do I have to take medications forever?

Beta blockers and heart failure medications are usually long-term. Antiarrhythmic medications such as amiodarone or sotalol may be tapered if VT becomes well-controlled and the underlying problem is addressed. The decision is individualized.

Is my family at risk?

If your VT is from coronary artery disease or hypertensive heart disease, your family shares your cardiovascular risk factors but doesn't directly inherit the arrhythmia. If your VT is from an inherited cardiomyopathy or a channelopathy, first-degree relatives may benefit from screening with EKG, echo, and sometimes genetic testing. We work this out case by case.

What about wearable devices and Apple Watch?

Consumer wearables can detect tachycardia and irregular rhythms but are not designed to definitively diagnose VT. If your device flags a fast rhythm and you have symptoms, get a real EKG. If you're asymptomatic and have no heart history, share the tracing with your doctor for context. Wearable data can be useful, especially when paired with clinical evaluation.

What is "stable" versus "unstable" VT?

Stable VT means the rhythm is sustained but the patient still has reasonable blood pressure and is awake and aware. Unstable VT means the patient is showing low blood pressure, chest pain, altered mental status, or other signs that the body isn't getting enough blood. The distinction guides whether we shock first or try medication.

Is caffeine or alcohol going to cause VT?

For most patients with structural VT, neither caffeine nor moderate alcohol is the trigger. Heavy alcohol use, especially binge drinking, can provoke arrhythmias including VT in susceptible hearts. Caffeine in moderate amounts is fine for most. If you notice a clear pattern between a particular intake and your symptoms, share that with your cardiologist.

Will my ICD shock me at random?

ICDs are programmed to deliver therapy only when the rhythm meets the criteria for VT or VF. Modern programming, informed by the MADIT-RIT trial in 2012, uses higher detection rate cutoffs and longer detection delays. That trial showed inappropriate shocks dropped by about 79 percent with these settings without compromising safety. If you're worried about shock anxiety, talk to your electrophysiology team about your specific programming.

When to Call Your Doctor

If you've been diagnosed with VT or have a defibrillator, call your cardiologist promptly for any of the following: a single ICD shock, lightheadedness or fainting that's new or different from before, palpitations that last longer than usual or that you can't terminate, new shortness of breath at rest, swelling in your legs that's worse than your baseline, chest pain or pressure, or new symptoms after starting any medication.

Call 911 or go to the emergency room for: multiple ICD shocks in a short time, prolonged loss of consciousness, chest pain with shortness of breath or sweating, or any cardiac arrest in someone near you.

A Final Word From Me

VT is a serious diagnosis, and I won't pretend otherwise. It also has more treatments now than it did even five years ago, with safer ablation, better mapping, smarter device programming, and a deeper understanding of which patients benefit from which therapy. If you've been given this diagnosis, you've already cleared the hardest hurdle, which is finding it. The next steps belong to your team, and you're entitled to a clear, calm conversation about what they are.

If you're a patient of mine reading this and want to talk through your specific situation, please bring this article to our next visit. Mark it up. Bring questions. The goal of every visit I have is to make sure you walk out understanding what's going on inside your chest and what we're going to do about it.

References

1. Al-Khatib, Sana M., William G. Stevenson, Michael J. Ackerman, et al. "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death." Journal of the American College of Cardiology 72, no. 14 (2018): e91-e220.

2. Zeppenfeld, Katja, Jacob Tfelt-Hansen, Marta de Riva, et al. "2022 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death." European Heart Journal 43, no. 40 (2022): 3997-4126.

3. Cronin, Edmond M., Frank M. Bogun, Philippe Maury, et al. "2019 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Catheter Ablation of Ventricular Arrhythmias." Heart Rhythm 17, no. 1 (2020): e2-e154.

4. Moss, Arthur J., Wojciech Zareba, W. Jackson Hall, et al. "Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction." New England Journal of Medicine 346, no. 12 (2002): 877-883.

5. Bardy, Gust H., Kerry L. Lee, Daniel B. Mark, et al. "Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure." New England Journal of Medicine 352, no. 3 (2005): 225-237.

6. Køber, Lars, Jens J. Thune, Jens C. Nielsen, et al. "Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure." New England Journal of Medicine 375, no. 13 (2016): 1221-1230.

7. Sapp, John L., George A. Wells, Ratika Parkash, et al. "Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs." New England Journal of Medicine 375, no. 2 (2016): 111-121.

8. Ortiz, Mercedes, Aida Martín, Francisco Arribas, et al. "Randomized Comparison of Intravenous Procainamide vs. Intravenous Amiodarone for the Acute Treatment of Tolerated Wide QRS Tachycardia: The PROCAMIO Study." European Heart Journal 38, no. 17 (2017): 1329-1335.

9. Moss, Arthur J., Claudio Schuger, Christopher A. Beck, et al. "Reduction in Inappropriate Therapy and Mortality through ICD Programming." New England Journal of Medicine 367, no. 24 (2012): 2275-2283.

10. Della Bella, Paolo, Jakub Baratto, Antonio Vergara, et al. "Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial." Circulation 145, no. 25 (2022): 1829-1838.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.